Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Live Streamed
On Demand
Back
Favorite
Email
Facebook
Tweet
Print
Clifford B. Jones, BSc MSc MB ChB (he/him/his)
Global medical lead
ViiV Healthcare, Brentford, UK, United Kingdom
Poster(s):
(P-534) Similar Efficacy, Safety and CD4 T-cell Increase up to Week 96 Observed with Fostemsavir (FTR)-Based Regimens in the BRIGHTE Study and Dolutegravir (DTG)-Based Regimens in the VIKING-3 Study in Individuals with Multidrug-Resistant (MDR) HIV-1
Thursday, October 17, 2024
12:15 PM – 1:30 PM
US PT
(P-574) Extrapolating Expected Efficacy, Safety, and Pharmacokinetics (PK) of Dolutegravir/Lamivudine (DTG/3TC) in Pregnant People Living with HIV-1 from Pregnancy Data with Combination DTG and/or 3TC Antiretroviral Therapies
Thursday, October 17, 2024
12:15 PM – 1:30 PM
US PT
(P-575) Evaluation of Weight Gain on Incident Hypertension among People Living with HIV-1 Receiving Dolutegravir (DTG)-Based Regimens or Comparator Antiretroviral Therapy (cART) in Randomized Clinical Trials through 96 Weeks
Thursday, October 17, 2024
12:15 PM – 1:30 PM
US PT
Email Clifford